Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider

Brittany A. Klein; Brittany A. Klein; Muhammad Ali Shazib; Alessandro Villa; Fábio de Abreu Alves; Fábio de Abreu Alves; Piamkamon Vacharotayangul; Piamkamon Vacharotayangul; Stephen Sonis; Stephen Sonis; Stefano Fedele; Stefano Fedele; Nathaniel S. Treister; Nathaniel S. Treister

doi:10.3389/froh.2022.968157

Frontiers in Oral Health (Aug 2022)

Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider

Brittany A. Klein,
Brittany A. Klein,
Muhammad Ali Shazib,
Alessandro Villa,
Fábio de Abreu Alves,
Fábio de Abreu Alves,
Piamkamon Vacharotayangul,
Piamkamon Vacharotayangul,
Stephen Sonis,
Stephen Sonis,
Stefano Fedele,
Stefano Fedele,
Nathaniel S. Treister,
Nathaniel S. Treister

Affiliations

Brittany A. Klein: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, United States
Brittany A. Klein: Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, United States
Muhammad Ali Shazib: Division of Surgical and Specialty Care, Workman School of Dental Medicine, High Point University, High Point, NC, United States
Alessandro Villa: Department of Orofacial Science, University of California San Francisco School of Dentistry, San Francisco, CA, United States
Fábio de Abreu Alves: A.C. Camargo Cancer Center, São Paulo, Brazil
Fábio de Abreu Alves: University of São Paulo School of Dentistry, São Paulo, Brazil
Piamkamon Vacharotayangul: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, United States
Piamkamon Vacharotayangul: Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, United States
Stephen Sonis: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, United States
Stephen Sonis: Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, United States
Stefano Fedele: Department of Clinical Research, Eastman Dental Institute, University College London, London, United Kingdom
Stefano Fedele: National Institute for Health and Care Research (NIHR) University College London Hospitals Biomedical Research Center, London, United Kingdom
Nathaniel S. Treister: Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, United States
Nathaniel S. Treister: Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, United States

DOI: https://doi.org/10.3389/froh.2022.968157
Journal volume & issue: Vol. 3

Abstract

Read online

Immune checkpoint inhibitors (ICIs) are a revolutionary class of antineoplastic therapy that restore anti-tumor immunity. Consequences of this enhanced immune response include a multitude of immune related adverse events (irAEs) that can affect any body system, including the mouth. Orofacial irAEs reproduce features of numerous immune-mediated conditions, including oral lichen planus, mucous membrane pemphigoid, and Sjögren syndrome, among others. The aim of this review is to summarize known orofacial irAEs and to familiarize oral healthcare providers with how to identify and manage these toxicities as part of the care team for patients treated with ICIs.

Published in Frontiers in Oral Health

ISSN: 2673-4842 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Dentistry
Website: https://www.frontiersin.org/journals/oral-health#

About the journal

Abstract

Keywords